Payment overview · 2025
General Payments
$4,010.18
63 reported records · 17 companies
Healthcare provider profile · identity verified
Michael Langiulli, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · MONROE, LA · NPI 1992765440
Verified facts
What the public records show
CMS Open Payments records show Michael Langiulli, MD received $4,010.18 in general payments during 2025 across 63 reported records.
Medtronic, Inc. accounted for 42.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Camzyos.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAMZYOS as an associated drug or biological on 41009 records involving 16400 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Camzyos by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 554 claims for Eliquis by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Nexlizet by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$1,699.52 | 42.4% | 15 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $1,575.95 | 39.3% | 11 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $177.19 | 4.4% | 10 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $111.22 | 2.8% | 5 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $76.46 | 1.9% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $57.36 | 1.4% | 4 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $54.38 | 1.4% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $48.89 | 1.2% | 2 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $42.35 | 1.1% | 2 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $40.21 | 1.0% | 2 | 2025 |
| Becton, Dickinson and Company | Unresolved — no canonical attribution shown | $19.71 | 0.5% | 1 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $18.99 | 0.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.33 | 0.5% | 1 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $18.09 | 0.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.04 | 0.5% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.71 | 0.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.78 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Travel and Lodging | $2,768.99 | 11 |
| Food and Beverage | $1,241.19 | 52 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ONYX FRONTIER Normalized: onyx frontier |
Device | Medtronic, Inc. | $1,642.35 | 12 | 2025 |
Source payment records
|
|||||
| JETSTREAM SC Normalized: jetstream sc |
Device | Boston Scientific Corporation | $1,337.98 | 2 | 2025 |
Source payment records
|
|||||
| General - Angiography Normalized: general angiography |
Device | Boston Scientific Corporation | $173.24 | 3 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $111.22 | 5 | 2025 |
Source payment records
|
|||||
| DIAMONDBACK CORONARY Normalized: diamondback coronary |
Device | Abbott Laboratories | $109.53 | 4 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $76.46 | 3 | 2025 |
Source payment records
|
|||||
| XIENCE SKYPOINT Normalized: xience skypoint |
Device | Abbott Laboratories | $67.66 | 6 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $57.36 | 4 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $54.38 | 2 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $49.63 | 5 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $42.35 | 2 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $40.21 | 2 | 2025 |
Source payment records
|
|||||
| COBALT DR MRI SURESCAN Normalized: cobalt dr mri surescan |
Device | Medtronic, Inc. | $23.02 | 1 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Becton, Dickinson and Company | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| CHOCOLATE Normalized: chocolate |
Device | Teleflex LLC | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $18.09 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.04 | 1 | 2025 |
Source payment records
|
|||||
| AZURE XT DR MRI SURESCAN Normalized: azure xt dr mri surescan |
Device | Medtronic, Inc. | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.71 | 1 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.78 | 1 | 2025 |
Source payment records
|
|||||
| General - Vascular Intervention Normalized: general vascular intervention |
Device | Boston Scientific Corporation | $15.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAMZYOS camzyos |
2025 | Camzyos | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | CAMZYOS open payments reported associated product |
CMS Open Payments — General Payments 41009 supporting records · 16400 recipient NPIs · example record 1184377697 |
Camzyos · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
554 | 113 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
144 | 39 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 614 | 173 |
| Atorvastatin Calcium | Atorvastatin Calcium | 604 | 184 |
| Eliquis | Apixaban | 554 | 113 |
| Amlodipine Besylate | Amlodipine Besylate | 419 | 115 |
| Clopidogrel | Clopidogrel Bisulfate | 335 | 81 |
| Carvedilol | Carvedilol | 295 | 71 |
| Valsartan | Valsartan | 291 | 67 |
| Lisinopril | Lisinopril | 286 | 77 |
| Furosemide | Furosemide | 263 | 83 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 249 | 74 |
| Metoprolol Tartrate | Metoprolol Tartrate | 210 | 68 |
| Losartan Potassium | Losartan Potassium | 190 | 54 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 182 | 49 |
| Hydralazine Hcl | Hydralazine Hcl | 173 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 165 | 46 |
| Entresto | Sacubitril/Valsartan | 144 | 39 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 142 | 42 |
| Ezetimibe | Ezetimibe | 126 | 28 |
| Flecainide Acetate | Flecainide Acetate | 120 | 22 |
| Xarelto | Rivaroxaban | 120 | 20 |
| Nifedipine Er | Nifedipine | 108 | 28 |
| Warfarin Sodium | Warfarin Sodium | 103 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 101 | 26 |
| Potassium Chloride | Potassium Chloride | 94 | 34 |
| Digoxin | Digoxin | 90 | 18 |
| Clonidine Hcl | Clonidine Hcl | 85 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 77 | 24 |
| Amiodarone Hcl | Amiodarone Hcl | 72 | 21 |
| Nebivolol Hcl | Nebivolol Hcl | 68 | 17 |
| Diltiazem 24hr Er | Diltiazem Hcl | 58 | 16 |
| Propafenone Hcl | Propafenone Hcl | 56 | 15 |
| Sotalol | Sotalol Hcl | 47 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | suppressed |
| Repatha Sureclick | Evolocumab | 40 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 39 | suppressed |
| Bumetanide | Bumetanide | 38 | suppressed |
| Brilinta | Ticagrelor | 37 | 11 |
| Spironolactone | Spironolactone | 35 | 14 |
| Camzyos | Mavacamten | 34 | suppressed |
| Ranolazine Er | Ranolazine | 34 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | 11 |
| Atenolol | Atenolol | 31 | suppressed |
| Nitroglycerin | Nitroglycerin | 30 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 29 | 12 |
| Jardiance | Empagliflozin | 28 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 28 | suppressed |
| Ramipril | Ramipril | 27 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Verapamil Er | Verapamil Hcl | 24 | suppressed |
| Metolazone | Metolazone | 22 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Cartia Xt | Diltiazem Hcl | 18 | suppressed |
| Simvastatin | Simvastatin | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Gabapentin | Gabapentin | 15 | suppressed |
| Omeprazole | Omeprazole | 15 | suppressed |
| Propafenone Hcl Er | Propafenone Hcl | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Dofetilide | Dofetilide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,010.18 · 63 records | Medtronic, Inc. | AMVUTTRA, AVVIGO Guidance System, AZURE XT DR MRI SURESCAN, Assure WCD, Attruby, CAMZYOS, CHOCOLATE, COBALT DR MRI SURESCAN, DIAMONDBACK CORONARY, General - Angiography, General - Vascular Intervention, JETSTREAM SC, Kerendia, LEQVIO, NEXLETOL, ONYX FRONTIER, Paradise Ultrasound Renal Denervation System, REPATHA, RotarexS 6 F x 135 cm, SYMPLICITY G3, VERQUVO, Wegovy, XIENCE SKYPOINT | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Camzyos play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error